January 30, 2012
Revenues up at Idexx for Q4
Revenues rose 8% in the fourth quarter at Idexx Laboratories in Westbrook, reaching $307.2 million, the company reported Friday.
The animal pharmaceutical company’s organic revenue growth, which excludes revenue from acquisitions, was 7% for the quarter ended Dec. 31. Earnings per diluted share increased 8% to $0.67. Chairman and CEO Jonathan Ayers said the company’s global reference laboratory and consulting services business grew 10% in the quarter and that sales for its instruments also rose.
Revenues for the year increased 10% to $1.219 billion, up from $1.103 billion in 2010. Organic revenue growth was 8%, according to the release.
Most Recent
Most Recent
Comments